ORG Wealth Partners LLC Buys 1,198 Shares of Kenvue Inc. $KVUE

ORG Wealth Partners LLC lifted its stake in Kenvue Inc. (NYSE:KVUE) by 6.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,492 shares of the company’s stock after purchasing an additional 1,198 shares during the period. ORG Wealth Partners LLC’s holdings in Kenvue were worth $409,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue during the 1st quarter worth approximately $30,000. TruNorth Capital Management LLC bought a new stake in shares of Kenvue during the first quarter valued at approximately $36,000. Truvestments Capital LLC purchased a new stake in Kenvue in the first quarter worth $37,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its position in Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock valued at $41,000 after buying an additional 929 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE:KVUE opened at $16.40 on Friday. The business’s 50-day moving average is $20.37 and its 200 day moving average is $21.83. Kenvue Inc. has a 12 month low of $16.07 and a 12 month high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $31.48 billion, a P/E ratio of 22.17, a P/E/G ratio of 2.32 and a beta of 0.83.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the previous year, the business posted $0.32 earnings per share. The business’s revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 5.1%. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s dividend payout ratio is presently 112.16%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on KVUE shares. UBS Group decreased their price target on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, July 17th. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Barclays dropped their price target on Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Tuesday, July 15th. Rothschild & Co Redburn raised Kenvue from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $22.50 to $22.00 in a research report on Friday. Finally, Evercore ISI dropped their target price on shares of Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $23.12.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.